Entering text into the input field will update the search result below

Fluidigm in-licenses next-gen sequencing assay from Baylor Genetics targeting cystic fibrosis gene

Aug. 17, 2017 4:25 PM ETStandard BioTools Inc. (LAB) StockBy: Douglas W. House, SA News Editor
  • Fluidigm (FLDM) inks an agreement with Baylor Genetics securing the rights to commercialize its CFTR library prep assay for research use with the automated Juno microfluidic system. The targeted next-generation sequencing (NGS) assay identifies variants from each of the 27 exons in the CFTR gene and selected areas within the gene. Mutations in the CFTR gene are responsible for cystic fibrosis.
  • Financial terms are not disclosed.

Recommended For You

More Trending News

About LAB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LAB--
Standard BioTools Inc.